•		
	q	L
	١	
	•	-
	-	
	ř	١
	7	•
ľ	٠	
۰	-	-

Plasmid	Leader	Gene	Promoter	Promoter Enhancer	Intron	Terminator
VR4700	VR4700 tissue plasminigen activator	influenza A/PR/8/34 nucleoprotein	CMV	CMV	CMV-A	mRBG
VR5900	hen egg lysozyme	hen egg lysozyme	CMV	CMV	CMV-A	mRBG
VR1412	not secreted	E. coli Lac Z	CMV	CMV	CMV-A	BGH
VR1623	mouse immunoglobulin	mouse Id/humanFc	CMV	CMV	CMV-A	BGH
VR1904 [human factor IX	human factor IX	CMV	CMV	CMV-A	ВСН

Figure 2

Cytofectin Structures

$$\begin{array}{ll} R = (CH_2)_9CH_3 & DDRIE \\ R = (CH_2)_{11}CH_3 & DLRIE \\ R = (CH_2)_{13}CH_3 & DMRIE \\ R = (CH_2)_8CH = CH(CH_2)_3CH_3 & DMORIE \\ R = (CH_2)_8CH = CH(CH_2)_7CH_3 & DORIE \end{array}$$

$$R = (CH_2)_{11}CH_3$$

$$R = (CH_2)_{13}CH_3$$

$$R = (CH_2)_8CH=CH(CH_2)_3CH_3$$

$$R = (CH_2)_{15}CH_3$$

DOSPA

Co-Lipid Structures


DOPE

DMPE

DPyPE

Cytofectin Structural Elements Determine the Level of Antibody Stimulation







4 / 14

Figure 4


Cytofectins Are Differentially Enhanced By Using DPyPE Instead of DOPE




Vaccine, Hartikka et al., Figure 5



Vaccine, Hartikka et al., Figure









7 / 14

Vaccine, Hartikka et al., Figure 4







WO 00/57917


PCT/US00/08282

8 / 14

Vaccine, Hartikka et al., Figure &










9 / 14


Vaccine, Hartikka et al., Figure






10 / 14

Vaccine, Hartikka et al., Figure | Ø










11 / 14

Figure 🕅

12 / 14










Figure 1/2

Figure 🖊 🎝

;*?**




Figure 机

